Imipenem/Cilastatine Acs Dobfar

Imipenem and Cilastatin, the active ingredient in Imipenem/Cilastatine Acs Dobfar, is a carbapenem antibiotic presented as an injection for intravenous use. It treats severe bacterial infections in hospitalized patients.

GNH USA supplies Imipenem/Cilastatine Acs Dobfar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Imipenem/Cilastatin is a broad‑spectrum carbapenem used to treat infections caused by susceptible bacteria. - Complicated intra‑abdominal infections: eradicates mixed‑flora pathogens and improves clinical outcomes. - Complicated urinary tract infections: clears resistant Gram‑negative organisms in the urinary system. - Complicated skin and soft‑tissue infections: resolves deep‑seated infections caused by resistant bacteria. - Hospital‑acquired bacterial pneumonia: provides coverage for multidrug‑resistant respiratory pathogens. - Septicemia: rapidly reduces bacterial load in bloodstream infections.

Adverse reactions may occur with any antimicrobial therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Elevated liver enzymes: transient increase in hepatic transaminases. - Injection site reactions: pain, erythema, or swelling. - Headache: occasional mild headache.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile colitis: antibiotic‑associated severe diarrhea. - Severe neutropenia: marked reduction in neutrophil count. - Thrombocytopenia: low platelet levels leading to bleeding risk. - Acute renal failure: sudden loss of kidney function.

Use Imipenem/Cilastatin with caution in specific clinical situations. - Renal function: assess creatinine clearance before initiating therapy. - Allergy: avoid in patients with known hypersensitivity to carbapenems or β‑lactams. - Seizure risk: monitor patients with a history of CNS disorders. - Drug interactions: review concomitant use of valproic acid and other interacting agents. - Pregnancy: prescribe only when the potential benefit justifies the potential risk to the fetus. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imipenem/Cilastatin may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Valproic acid: reduces serum levels of valproate, risking seizure breakthrough. - Ganciclovir: decreased antiviral activity when co‑administered. - Probenecid: may increase imipenem concentrations, heightening toxicity risk.

Moderate Interactions (Monitor Closely): - Loop diuretics: additive nephrotoxic potential; monitor renal function. - Aminoglycosides: increased risk of nephrotoxicity and ototoxicity; assess dosing and renal parameters.